The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia
Intervention: Rosuvastatin (Drug); aortic pulse wave velocity measurements (Procedure)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
AstraZeneca Crestor Medical Sciences Director, MD, Study Director, Affiliation: AstraZeneca
Summary
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in
hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
Clinical Details
Official title: The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
Secondary outcome: To investigate the effect of rosuvastatin compared to placebo on the aortic pressure wave in hemodialysis patients (at 3 months/ 6 months and 12 months).
Eligibility
Minimum age: 50 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signed informed consent, between 50 and 80 years of age, end stage renal failure
patients receiving hemodialysis
Exclusion Criteria:
- Received statins within past 6 months, a clear indication for use of lipid altering
drug, contra indication for lipid altering drug, history of statin induced myopathy
items in very
Locations and Contacts
Research Site, Nieuwegein, Netherlands
Additional Information
Starting date: October 2003
Last updated: October 16, 2005
|
